Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 6/20 | 1.00 |
| ▸ | POLA1 | P09884 | 1/20 | 0.60 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4384744 | 0.99 | XDH (1.00) | XDHPOLA1GDA | |
| SCHEMBL8535457 | 0.99 | XDH (1.00) | XDHPOLA1GDA | |
| Hydrochloric Acid SCHEMBL258899 | 0.97 | XDH (0.97) | XDHPOLA1GDA | |
| Hydrochloric Acid SCHEMBL30610398 | 0.96 | XDH (0.95) | XDHPOLA1GDA | |
| SCHEMBL6272738 | 0.96 | XDH (1.00) | XDHPOLA1GDA | |
| Acetic Acid SCHEMBL27671662 | 0.93 | XDH (0.88) | XDHPOLA1GDA | |
| SCHEMBL667798 | 0.90 | XDH (0.84) | XDHPOLA1GDA | |
| SCHEMBL5935074 | 0.87 | XDH (0.78) | XDHPOLA1GDA | |
| SCHEMBL8196752 | 0.86 | XDH (0.76) | XDHGDA | |
| SCHEMBL16197989 | 0.85 | XDH (0.77) | XDHGDA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | VDF FUTURECEUTICALS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | VDF FUTURECEUTICALS | 2007-07-12 | — | — | US | claimed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | claimed |
| CN-117344022-A | Composition for species and human sex identification, kit containing same and application | 山西医科大学 | 2024-01-05 | — | — | CN | disclosed |
| CN-116949191-A | Composition for meat adulteration identification, kit containing composition and application of kit | 山西医科大学 | 2023-10-27 | — | — | CN | disclosed |
| CN-116234585-A | Microtubule-associated protein TAU (MAPT) iRNA agent compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2023-06-06 | — | — | CN | disclosed |
| CN-116200476-A | Target analyte determination methods, mutant CsgG monomers, constructs, polynucleotides and oligo-wells thereof | 牛津纳米孔科技公开有限公司 | 2023-06-02 | — | — | CN | disclosed |
| CN-116064734-A | Nucleic acid amplification | 生命技术公司 | 2023-05-05 | — | — | CN | disclosed |
| CN-115298312-A | Leucine-rich repeat kinase 2 (LRRK 2) iRNA agent compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-114796255-A | Application of nicotinamide mononucleotide in protecting liver from being damaged | 深圳市旷逸生物科技有限公司 | 2022-07-29 | — | — | CN | disclosed |
| CN-114728018-A | Huntington (HTT) iRNA pharmaceutical compositions and methods of use thereof | 阿尔尼拉姆医药品有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2005020892-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| WO-2005016268-A2 | ALIMENTARY COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | MITOCHROMA RESEARCH, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| EP-0704445-B1 | Preparation of N-9 substituted guanine compounds | HOFFMANN LA ROCHE (CH) | 1999-04-21 | — | — | EP | disclosed |
| US-5565565-A | Preparation of N-9 substituted guanine compounds | SYNTEX (U.S.A.) INC. (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0704445-A1 | Preparation of N-9 substituted guanine compounds | F. Hoffmann-La Roche AG (CH) | 1996-04-03 | — | — | EP | disclosed |
| EP-0590361-A1 | Process for the preparation of 2-amino-6-halopurines | BASF Aktiengesellschaft (DE) | 1994-04-06 | — | — | EP | disclosed |
| US-4914131-A | HERPES SIMPLEX VIRUS; LIDOCAINE OR ITS SALTS | Brigham, Dana P. (US) | 1990-04-03 | — | — | US | disclosed |
| US-4757088-A | Administering lidocaine and pantothenic acid; herpes | Brigham, Dana P. (US) | 1988-07-12 | — | — | US | disclosed |
| US-4628063-A | LIDOCAINE, PANTOTHENOL, HERPES | Brigham, Dana P. (US) | 1986-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161582-A1 | Pharmaceutical compositions and methods for metabolic modulation | GPR119, PRKAG2, PRKAG1 | XDH 734/4885POLA1 4465/4885GDA 671/4885 |
| US-20090203638-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR METABOLIC MODULATION | GPR119, PRKAG2, GCKR | XDH 726/4885POLA1 4543/4885GDA 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.